--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About GALT20260417C5
Biological Technology
Galectin Therapeutics Inc., established in July 2000 as Pro Pharma, is a development-stage company engaged in drug development to create new therapies for cancer and fibrotic diseases. Glaxti's drug candidate is based on an approach targeting the galactoagglutinin protein, a key mediator of biological and pathological functions. Glaxti uses naturally occurring, readily available plant materials as raw materials to create proprietary complex carbohydrates with specific molecular weights and pharmaceutical properties during the production process.
